This article is more than 5 years old. Information may no longer be current.
Fixed combination dosing lowers IOP more than individual components
Click Here to Manage Email Alerts
CORONADO, Calif. — An “astounding” 40% reduction in IOP achieved with one drug given once a day was achieved in 35% of patients taking a fixed-dose combination of netarsudil and latanoprost, according to a speaker here.
Sanjay Asrani, MD, updated colleagues at the American Glaucoma Society meeting on the 3-month interim results of the Mercury 1 trial, a double-masked, randomized, multicenter, active-controlled, parallel-group 12-month phase 3 study comparing safety and efficacy of a fixed-dose prostaglandin combination with safety and efficacy of each of its components.
Sanjay Asrani
A total of 718 patients were randomized 1:1:1 to receive Roclatan (netarsudil 0.02%, latanoprost ophthalmic solution 0.005%, Aerie Pharmaceuticals), netarsudil 0.02% or latanoprost ophthalmic solution 0.005%. Baseline demographics were similar in all three groups.
At 3 months, the intend to treat results showed the fixed-dose combination differed from its individual components by 1.5 mm Hg to 2.5 mm Hg, demonstrating greater efficacy, Asrani said. In the fixed-dose combination group, 82% of patients achieved 18 mm Hg or lower IOP.
Even “more remarkable,” Asrani said, was that 61% of patients in the fixed-dose combination group achieved less than 16 mm Hg pressure compared with 39% in the latanoprost group, and 33% achieved pressures less than 14 mm Hg compared with 15% in the latanoprost group.
“These are the first times we’re seeing pressures as low as under 14 mm Hg with one drug dosed once a day,” Asrani said. – by Patricia Nale, ELS
Reference:
Asrani S. A 3-month interim report of a prospective 12-month study assessing the safety and ocular hypotensive efficacy of PG324 ophthalmic solution (FDC) compared to netarsudil 0.02% and latanoprost 0.005% in subjects with elevated IOP (Mercury 1). Presented at: American Glaucoma Society annual meeting; March 2-5, 2017; Coronado, Calif.
Disclosure: Asrani reports he is a consultant for Roche, Dose Medical and Camras Vision and receives honoraria from Heidelberg Engineering.